somatostatin analogue
Octreotide
Answer
Octreotide is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 344 registered trials, 50 of them running. Brand names on the FDA label register: Octreotide Acetate, Bynfezia Pen, Sandostatin and Mycapssa.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
344 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 49 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 224 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Octreotide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 344 trials
| NCT02019706 | Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome currently recruiting participants · register updated 2026-10-02 |
|---|---|
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, Hig running, but no longer enrolling · register updated 2026-10-01 |
| NCT07583563 | An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly currently recruiting participants · register updated 2026-09-25 |
| 2024-516616-24-00 | A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and no status recorded · register updated 2026-09-23 |
| 2023-507443-10-00 | A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 a no status recorded · register updated 2026-09-18 |
| 2024-519667-18-00 | Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hyd no status recorded · register updated 2026-09-17 |
| NCT06878664 | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors currently recruiting participants · register updated 2026-09-16 |
| NCT07663318 | A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Eff completed · register updated 2026-09-16 |
| NCT06784752 | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET currently recruiting participants · register updated 2026-09-11 |
| NCT07814651 | A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patie completed · register updated 2026-09-11 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.